SNU251 ovarian cancer cell line carrying truncation of 49 C-terminal aminoacids of the BRCA1 gene (partial deletion of 2nd BRCT domain) demonstrated increased sensitivity to paclitaxel in a cell viability assay; this effect was reversed by the introduction of the wild-type BRCA1. The gene discussed is BRCA1; the disease is ovarian carcinoma.